Crowded psoriasis market cuts Lilly's mirikizumab ambitions

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested. 

California's AMT is latest biotech aiming to go public in pa...

California’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming to raise $100 million to take an oral ulcerative colitis drug into phase

Janssen trials ultrasound-guided approach to treating Crohn'...

In the highly competitive market for inflammatory diseases such as Crohn's, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as

Sosei Heptares bags another big partnership, this time with ...

Drugs could mimic gut bacteria benefits to treat diabetes

It may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat diseases such as type II diabetes, a new study has found.

AZ joins with Seres to research role of gut microbiome in ca...

AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of the gut microbiome in order to increase effica